

Paul P Dobesh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3673436/publications.pdf>

Version: 2024-02-01

78
papers

2,233
citations

331538

21
h-index

223716

46
g-index

79
all docs

79
docs citations

79
times ranked

3416
citing authors

#	ARTICLE	IF	CITATIONS
1	Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial. <i>Thrombosis and Haemostasis</i> , 2022, 122, 131-141.	1.8	55
2	Selatogrel: A Novel Subcutaneous P2Y12 Inhibitor. <i>Journal of Cardiovascular Pharmacology</i> , 2022, 79, 161-167.	0.8	6
3	Real-world management of oral factor Xa inhibitor-related bleeds with reversal or replacement agents including andexanet alfa and four-factor prothrombin complex concentrate: a multicenter study. <i>Future Cardiology</i> , 2021, 17, 127-135.	0.5	24
4	Direct Oral Anticoagulants in the Treatment of Venous Thromboembolism: Use in Patients with Advanced Renal Impairment, Obesity, or Other Weight-Related Special Populations. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2021, 42, 233-249.	0.8	2
5	Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1620.	3.8	515
6	When the Simulation Becomes Real. <i>American Journal of Pharmaceutical Education</i> , 2021, , 8552.	0.7	0
7	Dual Antiplatelet Therapy for Long-term Secondary Prevention of Atherosclerotic Cardiovascular Events. <i>Clinical Therapeutics</i> , 2020, 42, 2084-2097.	1.1	4
8	Coagulopathy, Venous Thromboembolism, and Anticoagulation in Patients with COVID-19. <i>Pharmacotherapy</i> , 2020, 40, 1130-1151.	1.2	63
9	The Impact of Eliminating Backward Navigation on Computerized Examination Scores and Completion Time. <i>American Journal of Pharmaceutical Education</i> , 2020, 84, ajpe8034.	0.7	1
10	Antidotes for reversal of direct oral anticoagulants. , 2019, 204, 107405.		9
11	Betrixaban: Safely Reducing Venous Thromboembolic Events with Extended Prophylaxis. <i>American Journal of Medicine</i> , 2019, 132, 307-311.	0.6	3
12	Contemporary Management of Direct Oral Anticoagulants During Cardioversion and Ablation for Nonvalvular Atrial Fibrillation. <i>Pharmacotherapy</i> , 2019, 39, 94-108.	1.2	2
13	Pharmacology of Oral Anticoagulants. , 2019, , 11-34.		2
14	Periprocedural Management of Direct Oral Anticoagulants Surrounding Cardioversion and Invasive Electrophysiological Procedures. <i>Cardiology in Review</i> , 2018, 26, 245-254.	0.6	2
15	Extended Venous Thromboembolism Prophylaxis in Medically Ill Patients. <i>Pharmacotherapy</i> , 2018, 38, 597-609.	1.2	10
16	Venous thromboembolism in acute medically ill patients: identifying unmet needs and weighing the value of prophylaxis. <i>American Journal of Managed Care</i> , 2018, 24, S468-S474.	0.8	1
17	The use of betrixaban for extended prophylaxis of venous thromboembolism events in hospitalized, high-risk patients. <i>American Journal of Managed Care</i> , 2018, 24, S475-S482.	0.8	0
18	Best practices for implementing venous thromboembolism prophylaxis across the continuum of care. <i>American Journal of Managed Care</i> , 2018, 24, S483-S488.	0.8	0

#	ARTICLE	IF	CITATIONS
19	Renal Function Considerations for Stroke Prevention in Atrial Fibrillation. American Journal of Medicine, 2017, 130, 1015-1023.	0.6	38
20	2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants. Journal of the American College of Cardiology, 2017, 70, 3042-3067.	1.2	285
21	Renal Function and Direct Oral Anticoagulant Treatment for Venous Thromboembolism. American Journal of Medicine, 2017, 130, 1137-1143.	0.6	7
22	The PARTHENON Clinical Development Program: the Role of Ticagrelor in Patients with Atherothrombotic Disease. Cardiovascular Drugs and Therapy, 2017, 31, 433-444.	1.3	4
23	Management of Periprocedural Anticoagulation. Journal of the American College of Cardiology, 2016, 68, 217-226.	1.2	45
24	Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism. Journal of Thrombosis and Thrombolysis, 2016, 41, 165-186.	1.0	156
25	Clopidogrel Response Variability. Journal of Pharmacy Practice, 2016, 29, 26-34.	0.5	24
26	Management of Venous Thromboembolism. Annals of Pharmacotherapy, 2016, 50, 486-501.	0.9	21
27	Antiplatelet Agents in Cardiology: A Report on Aspirin, Clopidogrel, Prasugrel, and Ticagrelor. Current Pharmaceutical Design, 2016, 22, 1918-1932.	0.9	8
28	Reducing The Risk Of Stroke In Patients With Nonvalvular Atrial Fibrillation With Direct Oral Anticoagulants. Is One Of These Not Like The Others?. Journal of Atrial Fibrillation, 2016, 9, 1481.	0.5	5
29	Key Articles and Guidelines in the Management of Hypertension. Journal of Pharmacy Practice, 2015, 28, 146-161.	0.5	3
30	Direct Oral Anticoagulants for the Prevention of Stroke in Patients with Nonvalvular Atrial Fibrillation: Understanding Differences and Similarities. Drugs, 2015, 75, 1627-1644.	4.9	37
31	Cangrelor for treatment during percutaneous coronary intervention. Future Cardiology, 2014, 10, 201-213.	0.5	3
32	Statins role in the prevention and treatment of sepsis. Pharmacological Research, 2014, 88, 31-40.	3.1	29
33	New Oral Anticoagulants for the Treatment of Venous Thromboembolism: Understanding Differences and Similarities. Drugs, 2014, 74, 2015-2032.	4.9	21
34	Economic Implications of Inadequate Treatment of Venous Thromboembolism and Potential Solutions. Journal of Pharmacy Practice, 2014, 27, 178-186.	0.5	5
35	Ticagrelor: Pharmacokinetics, Pharmacodynamics, Clinical Efficacy, and Safety. Pharmacotherapy, 2014, 34, 1077-1090.	1.2	161
36	Prevalence of CYP2C19 variant alleles and pharmacodynamic variability of aspirin and clopidogrel in Native Americans. American Heart Journal, 2014, 167, 413-418.	1.2	13

#	ARTICLE	IF	CITATIONS
37	Measuring or Monitoring of Novel Anticoagulants: Which Laboratory Test to Request?. Current Emergency and Hospital Medicine Reports, 2013, 1, 208-216.	0.6	3
38	Role of the Pharmacist in Achieving Performance Measures to Improve the Prevention and Treatment of Venous Thromboembolism. Pharmacotherapy, 2013, 33, 650-664.	1.2	18
39	Novel Direct-Acting Anticoagulants for Risk Reduction in ACS. Journal of Pharmacy Practice, 2013, 26, 358-366.	0.5	3
40	Key Articles and Guidelines in the Management of Acute Coronary Syndrome and in Percutaneous Coronary Intervention: 2012 Update. Pharmacotherapy, 2012, 32, e348-86.	1.2	12
41	Adherence and dosing frequency of common medications for cardiovascular patients. American Journal of Managed Care, 2012, 18, 139-46.	0.8	54
42	Key Articles and Guidelines in the Management of Peripheral Arterial Disease. Pharmacotherapy, 2011, 31, 922-922.	1.2	4
43	Statins in Sepsis. Journal of Pharmacy Practice, 2010, 23, 38-49.	0.5	9
44	Anticoagulation in the Management of Non-ST-Segment Elevation Acute Coronary Syndrome. Journal of Pharmacy Practice, 2010, 23, 324-334.	0.5	1
45	Anticoagulation in the Management of ST-Segment Elevation Myocardial Infarction. Journal of Pharmacy Practice, 2010, 23, 335-343.	0.5	0
46	Potential unrecognised costs of clopidogrel pretreatment in acute coronary syndrome. Journal of Medical Economics, 2009, 12, 325-330.	1.0	2
47	Key Articles and Guidelines in the Treatment of Venous Thromboembolism. Pharmacotherapy, 2009, 29, 1385-1385.	1.2	11
48	Clopidogrel versus Prasugrel: Times Are Changing, but Not for Everyone. Pharmacotherapy, 2009, 29, 1393-1396.	1.2	7
49	Key Articles and Guidelines for the Prevention of Venous Thromboembolism. Pharmacotherapy, 2009, 29, 410-458.	1.2	19
50	Pharmacologic Therapy for Intermittent Claudication. Pharmacotherapy, 2009, 29, 526-553.	1.2	10
51	Reduction in Mortality Associated with Statin Therapy in Patients with Severe Sepsis. Pharmacotherapy, 2009, 29, 621-630.	1.2	77
52	Economic Burden of Venous Thromboembolism in Hospitalized Patients. Pharmacotherapy, 2009, 29, 943-953.	1.2	113
53	Pharmacokinetics and Pharmacodynamics of Prasugrel, a Thienopyridine P2Y12 Inhibitor. Pharmacotherapy, 2009, 29, 1089-1102.	1.2	78
54	Clinically important interaction between statin drugs and Clostridium difficile toxin?. Medical Hypotheses, 2009, 73, 1045-1047.	0.8	20

#	ARTICLE	IF	CITATIONS
55	Optimizing antithrombotic therapy in patients with non-ST-segment elevation acute coronary syndrome. American Journal of Health-System Pharmacy, 2008, 65, S22-S28.	0.5	5
56	Improving the use of anticoagulant therapies in acutely ill medical patients. American Journal of Health-System Pharmacy, 2008, 65, S5-S12.	0.5	9
57	Are Hospitals Following Guidelines for VTE Prevention? the Venous Thromboembolism Study to Assess the Rate of Thromboprophylaxis. Blood, 2008, 112, 1286-1286.	0.6	1
58	Bias in <i>AJHP</i> supplements. American Journal of Health-System Pharmacy, 2008, 65, 2329-2330.	0.5	0
59	Ranolazine: A New Option in the Management of Chronic Stable Angina. Pharmacotherapy, 2007, 27, 1659-1676.	1.2	12
60	Traditional Management of Chronic Stable Angina. Pharmacotherapy, 2007, 27, 1677-1692.	1.2	11
61	Key Articles and Guidelines in the Management of Acute Coronary Syndromes and in Percutaneous Coronary Intervention: 2007 Update. Pharmacotherapy, 2007, 27, 1722-1758.	1.2	5
62	Stable Angina. Journal of Managed Care Pharmacy, 2006, 12, S4-S9.	2.2	2
63	Critical Pathways: The Role of Pharmacy Today and Tomorrow. Pharmacotherapy, 2006, 26, 1358-1368.	1.2	16
64	Choosing the Appropriate Antithrombotic Agent for the Prevention and Treatment of VTE: A Case-Based Approach. Annals of Pharmacotherapy, 2006, 40, 1558-1571.	0.9	9
65	Managing hypertension in patients with type 2 diabetes mellitus. American Journal of Health-System Pharmacy, 2006, 63, 1140-1149.	0.5	17
66	Effect of a Clinical Pharmacy Education Program on Improvement in the Quantity and Quality of Venous Thromboembolism Prophylaxis for Medically Ill Patients. Journal of Managed Care Pharmacy, 2005, 11, 755-762.	2.2	57
67	Commentary. Evidence-based Cardiovascular Medicine, 2005, 9, 182-183.	0.0	0
68	Key Articles and Guidelines Relative to Treatment of Patients with Acute Coronary Syndromes. Pharmacotherapy, 2004, 24, 105-144.	1.2	7
69	Evidence for Extended Prophylaxis in the Setting of Orthopedic Surgery. Pharmacotherapy, 2004, 24, 73S-81S.	1.2	7
70	Unfractionated Heparin Dosing Nomograms: Road Maps to Where?. Pharmacotherapy, 2004, 24, 142S-145S.	1.2	5
71	Economics of Unfractionated Heparin: Beyond Acquisition Cost. Pharmacotherapy, 2004, 24, 161S-164S.	1.2	2
72	Ximelagatran: Pharmacology, Pharmacokinetics, and Pharmacodynamics. Pharmacotherapy, 2004, 24, 169S-178S.	1.2	2

#	ARTICLE	IF	CITATIONS
73	Drug-Eluting Stents: A Mechanical and Pharmacologic Approach to Coronary Artery Disease. <i>Pharmacotherapy</i> , 2004, 24, 1554-1577.	1.2	28
74	Outcomes with Changes in Prescribing of Glycoprotein IIb/IIIa Inhibitors in PCI. <i>Annals of Pharmacotherapy</i> , 2003, 37, 1375-1380.	0.9	0
75	Novel concepts: Emerging data and the role of extended prophylaxis following hip fracture surgery. <i>American Journal of Health-System Pharmacy</i> , 2003, 60, S15-S19.	0.5	5
76	Knowledge of Hospital Acquisition Costs of Antibiotics among Physicians in a Community Hospital. <i>Hospital Pharmacy</i> , 2002, 37, 833-839.	0.4	1
77	Administration of Glycoprotein IIb-IIIa Inhibitors in Patients with ST-Segment Elevation Myocardial Infarction. <i>Pharmacotherapy</i> , 2002, 22, 864-888.	1.2	2
78	Prevention of Venous Thromboembolism in Acute Medical Illness. <i>Pharmacotherapy</i> , 2002, 22, 1564-1578.	1.2	25